Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | CCNC | P24863 | 2/20 | 0.42 |
| ▸ | CDK8 | P49336 | 2/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 7/20 | 0.42 |
| ▸ | FLT3 | P36888 | 8/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.39 |
| ▸ | EML4 | Q9HC35 | 2/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24944183 | 1.00 | SYK (0.44) | SYKCCNCCDK8PDGFRAFLT3 | |
| SCHEMBL24944792 | 0.93 | CAMK2D (0.40) | SYKCCNCCDK8PDGFRAFLT3 | |
| SCHEMBL30205550 | 0.93 | CAMK2D (0.40) | SYKCCNCCDK8PDGFRAFLT3 | |
| SCHEMBL24944172 | 0.93 | TBK1 (0.39) | SYKCCNCCDK8PDGFRAFLT3 | |
| SCHEMBL24943840 | 0.92 | IKBKE (0.46) | SYKFLT3CDK2AURKACCNA2 | |
| SCHEMBL30205589 | 0.92 | IKBKE (0.46) | SYKFLT3CDK2AURKACCNA2 | |
| SCHEMBL24944494 | 0.92 | LRRK2 (0.42) | SYKCCNCCDK8PDGFRAAURKA | |
| SCHEMBL29173415 | 0.92 | CCNC (0.42) | SYKCCNCCDK8PDGFRAFLT3 | |
| SCHEMBL24943841 | 0.91 | SYK (0.38) | SYKCCNCCDK8PDGFRAFLT3 | |
| Formic Acid SCHEMBL30205666 | 0.90 | TBK1 (0.37) | SYKCCNCCDK8PDGFRAFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373817-B1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2025-05-21 | — | — | EP | claimed |
| EP-4373817-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2024-05-29 | — | — | EP | claimed |
| CN-117693503-A | Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2024-03-12 | — | — | CN | claimed |
| WO-2023001794-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-01-26 | — | — | WO | claimed |
| EP-4373817-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2024-05-29 | — | — | EP | disclosed |
| CN-117693503-A | Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2024-03-12 | — | — | CN | disclosed |
| WO-2023001794-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-01-26 | — | — | WO | disclosed |